ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

Acquired Bleeding Disorders » Novel Therapies in the Management of Acquired Bleeding

Theme Navigation

  • ISTH 2022 Congress
    • Acquired Bleeding Disorders
      • Novel Therapies in the Management of Acquired Bleeding

Abstract Number: PO0048

A Cardiac Amyloidosis Presentation: Atrial Mass Versus Thrombus

F. Alayoubi1, G. Elgohary2

Abstract Number: PB1001

A Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Hemostatic and Anti-Inflammatory Activities

A. Fager1, M. Hoffman2, D. Monroe3

Abstract Number: PB1003

CT-001 is a Rapid Clearing Factor VIIa with Enhanced Hemostatic Activity and Safety in Mouse Models of Acute Bleeding

D. Sim, C. Mallari, J. Teare, M. Bauzon, T. Hermiston

Abstract Number: PB1002

Daratumumab as an Adjunctive Therapy for Acquired Hemophilia A with Poor Prognostic Markers

C. Moonla1, C. Polprasert1, S. Krittikarux2, S. Krajibthong3, T. Chajuwan4, A. Sukperm1, B. Akkawat1, P. Rojnuckarin1, N. Uaprasert1

Abstract Number: VPB1006

Mini-invasive surgical treatment of haemorrhoiadal bleeding in patients with cardiovascular disease under antithrombotic therapy

A. Tsitskarava

Abstract Number: PB0008

Neutralizing anti-emicizumab antibodies in a patient with Acquired Hemophilia A

B. Pezeshkpoor1, N. Sereda1, A. Berkemeier1, J. Müller2, S. Singh1, S. Ramaraje Urs2, C. Klein1, S. Horneff1, G. Goldmann1, N. Marquardt1, J. Oldenburg3

Abstract Number: VPB1007

Overview of Hemostatic Effects of Exogenous Fibrin Monomer with Systemic Use in the Experiment

V. Vdovin1, I. Shakhmatov1, A. Momot2

Abstract Number: PB0007

Post-partum Acquired Haemophilia A in the COVID era – building the case for Emicizumab?

C. Crossette-Thambiah1, D. Arachchillage2, M. Laffan3

Abstract Number: PB1005

Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors

D. Verhoef1, T. Gomes2, G. Short3, P. Reitsma1

Abstract Number: OC 61.4

Supercharged platelets as a novel therapy for reducing blood loss post-cardiac surgery

A. Crosby1, S. Mookerjee1, A. Waller2, H. Foster3, C. Ghevaert4

Abstract Number: PB1000

The Loss of High Molecular Weight Von Willebrand Factor Multimers under Shear Conditions in Sheep is Not Solely ADAMTS13 Dependent

S. Deconinck1, A. Schelpe2, I. Pareyn1, A. Vandenbulcke1, C. Tersteeg3, S. De Meyer3, K. Vanhoorelbeke3

Abstract Number: PB0999

Update in The Management Tools of Thrombotic Thrombocytopenic Purpura(TTP) As One of the Rare Hematological Disorders with A Highlight On the Cost Value of Such Diseases

F. Alayoubi1, G. Elgohary2

Abstract Number: OC 24.3

VMX-C001 is an effective factor Xa inhibitor reversal agent and displays a favorable pharmacodynamic profile in animal models

D. Verhoef1, T. Gomes2, H. Spronk3, G. Short4, P. Reitsma1

Abstract Number: PB1004

Waste not, want not: evaluating the hemostatic properties of novel plasma supernatants produced from late-storage low-titer type O whole blood

A. Srinivasan*1, E. Mihalko*2, K. Rahn2, J. Seheult3, P. Spinella4, A. Cap5, D. Triulzi6, M. Yazer6, M. Neal2, S. Shea7

« View all themes from the ISTH 2022 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley